An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
DexCom, Inc. (DXCM) plans to release its Q4 and FY 2023 financial results on February 8, 2024, followed by a conference call to review performance. The call will be webcast and archived on the investor relations website. Dial-in details are provided for listening to the conference call.
Positive
None.
Negative
None.
SAN DIEGO--(BUSINESS WIRE)--
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2023 financial results after market close on Thursday, February 8, 2024. Management will hold a conference call to review the company's fourth quarter and fiscal year 2023 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference.
To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the start time.
About DexCom, Inc.
DexCom, Inc. empowers people to take real-time control of health through innovative continuous glucose monitoring (CGM) systems. Headquartered in San Diego, Calif., and with operations across Europe and select parts of Asia/Oceania, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of users, caregivers, and providers, Dexcom works to simplify and improve diabetes management around the world. For more information about Dexcom CGM, visit www.dexcom.com.
DexCom, Inc.:
Sean Christensen
Vice President – Finance and Investor Relations
investor-relations@dexcom.com
(858) 200-0200
Source: DexCom, Inc.
DexCom plans to release its Q4 and FY 2023 financial results after market close on Thursday, February 8, 2024.
The ticker symbol for DexCom is DXCM.
The conference call will be webcast and archived on the Dexcom investor relations website at investors.dexcom.com.
To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID '9430114' approximately five minutes prior to the start time.
founded in 1999, dexcom, inc provides continuous glucose monitoring technology to help patients and their clinicians better manage diabetes. since our inception, we have focused on better outcomes for patients, caregivers, and clinicians by delivering solutions for people with diabetes — while empowering our community to take control of diabetes.